Time-varying association of first-line bevacizumab with progression-free survival in advanced ovarian cancer: A multicenter matched cohort study.
Randomized trials have demonstrated that first-line bevacizumab extends progression-free survival (PFS) in advanced ovarian cancer. However, its long-term effectiveness in routine clinical practice remains unclear. This study investigated the time-varying association between first-line bevacizumab and PFS in patients n...